{"org_id": "T000025702", "org_name_cn": "深圳信立泰药业股份有限公司", "org_short_name_cn": "信立泰", "org_name_en": "Shenzhen Salubris Pharmaceuticals Co.,Ltd.", "org_short_name_en": "Salubris", "main_operation_business": "药品、医疗器械产品的研发、生产、销售。", "operating_scope": "　　货物及技术进出口业务（不含进口分销业务）；自有物业租赁。药品的研发、技术转让，技术咨询。（以上项目不涉及外商投资准入特别管理措施，项目涉及应取得许可审批的，须凭相关审批可经营）以下项目涉及应取得许可审批的，须凭相关审批文件方可经营：开发研究、生产化学原料药、粉针剂、片剂、胶囊。", "district_encode": "440304", "org_cn_introduction": "深圳信立泰药业股份有限公司主营业务药品、医疗器械产品的研发、生产、销售。主要产品及在研项目包括心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物等，涵盖心血管、抗肿瘤、降血糖、抗感染、骨科、抗肿瘤等治疗领域。截至报告期末，公司累计拥有有效专利授权205件，其中国际授权51项；正在申请148件，其中国际申请61项（含PCT申请16项）。", "legal_representative": "叶澄海", "general_manager": "叶宇翔", "secretary": "杨健锋", "established_date": 910022400000, "reg_asset": 1114816535.0, "staff_num": 3448, "telephone": "86-755-83867888", "postcode": "518040", "fax": "86-755-83867338", "email": "investor@salubris.com", "org_website": "www.salubris.com", "reg_address_cn": "广东省深圳市福田区深南大道6009号车公庙绿景广场主楼37层", "reg_address_en": "", "office_address_cn": "广东省深圳市福田区深南大道6009号车公庙绿景广场主楼37层", "office_address_en": "", "currency_encode": "019001", "currency": "CNY", "listed_date": 1252512000000, "provincial_name": "广东省", "actual_controller": "叶澄海 (42.74%)，廖清清 (14.25%)，陈志明 (1.82%)，叶宇翔，叶宇筠", "classi_name": "民营企业", "pre_name_cn": null, "chairman": "叶澄海", "executives_nums": 16, "actual_issue_vol": 28500000.0, "issue_price": 41.98, "actual_rc_net_amt": 1140673700.0, "pe_after_issuing": 41.77, "online_success_rate_of_issue": 0.6613, "affiliate_industry": {"ind_code": "BK0040", "ind_name": "化学制药"}}